{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:42:32Z","timestamp":1792662152302,"version":"4.5.0"},"reference-count":29,"publisher":"e-Century Publishing Corporation","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/nbwe4011","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T02:53:22Z","timestamp":1767754402000},"page":"9451-9459","source":"Crossref","is-referenced-by-count":0,"title":["Verapamil and venlafaxine combined as an effective and well-tolerated adjunct for cancer pain management"],"prefix":"10.62347","volume":"17","author":[{"given":"Qian","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers15030591","article-title":"Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis","volume":"15","author":"Snijders","year":"2023","unstructured":"Snijders RAH, Brom L, Theunissen M and van den Beuken-van Everdingen MHJ. Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel) 2023; 15: 591.","journal-title":"Cancers (Basel)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3904\/kjim.2018.162","article-title":"Neuropathic cancer pain: prevalence, pathophysiology, and management","volume":"33","author":"Yoon","year":"2018","unstructured":"Yoon SY and Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med 2018; 33: 1058-1069.","journal-title":"Korean J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/cancers14081992","article-title":"Treatment of neuropathic pain directly due to cancer: an update","volume":"14","author":"Shkodra","year":"2022","unstructured":"Shkodra M and Caraceni A. Treatment of neuropathic pain directly due to cancer: an update. Cancers (Basel) 2022; 14: 1992.","journal-title":"Cancers (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ejca.2008.03.022","article-title":"Management of cancer pain: basic principles and neuropathic cancer pain","volume":"44","author":"Laird","year":"2008","unstructured":"Laird B, Colvin L and Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. Eur J Cancer 2008; 44: 1078-1082.","journal-title":"Eur J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1533-2500.2011.00485.x","article-title":"Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature","volume":"12","author":"Vadalouca","year":"2012","unstructured":"Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P and Siafaka I. Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract 2012; 12: 219-251.","journal-title":"Pain Pract"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2017.00286","article-title":"Discovery and development of calcium channel blockers","volume":"8","author":"Godfraind","year":"2017","unstructured":"Godfraind T. Discovery and development of calcium channel blockers. Front Pharmacol 2017; 8: 286.","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1526-4610.2008.01298.x","article-title":"Clinical pharmacology and possible mode of action","volume":"49","author":"Tfelt-Hansen","year":"2009","unstructured":"Tfelt-Hansen P and Tfelt-Hansen J. Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache 2009; 49: 117-125.","journal-title":"Headache"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0022-3565(24)39245-6","article-title":"Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein","volume":"293","author":"Pauli-Magnus","year":"2000","unstructured":"Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M and Fromm MF. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000; 293: 376-382.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"505876","DOI":"10.1155\/2014\/505876","article-title":"Analgesia synergism of essential oil from pericarp of zanthoxylum schinifolium and verapamil","volume":"2014","author":"Wu","year":"2014","unstructured":"Wu G and Wu H. Analgesia synergism of essential oil from pericarp of zanthoxylum schinifolium and verapamil. Evid Based Complement Alternat Med 2014; 2014: 505876.","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neulet.2004.02.049","article-title":"Mechanical and thermal anti-nociception in rats after systemic administration of verapamil","volume":"360","author":"Todorovic","year":"2004","unstructured":"Todorovic SM, Pathirathna S, Meyenburg A and Jevtovic-Todorovic V. Mechanical and thermal anti-nociception in rats after systemic administration of verapamil. Neurosci Lett 2004; 360: 57-60.","journal-title":"Neurosci Lett"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jocn.2023.05.013","article-title":"Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: a systematic review","volume":"113","author":"Collins","year":"2023","unstructured":"Collins L, Lam L, Kleinig O, Proudman W, Zhang R, Bagster M, Kovoor J, Gupta A, Goh R, Bacchi S, Schultz D and Kleinig T. Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: a systematic review. J Clin Neurosci 2023; 113: 130-141.","journal-title":"J Clin Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/eujp.2001.0266","article-title":"Venlafaxine in neuropathic pain following treatment of breast cancer","volume":"6","author":"Tasmuth","year":"2002","unstructured":"Tasmuth T, Härtel B and Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002; 6: 17-24.","journal-title":"Eur J Pain"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/pm\/pnw261","article-title":"Treatment of neuropathic pain with venlafaxine: a systematic review","volume":"18","author":"Aiyer","year":"2017","unstructured":"Aiyer R, Barkin RL and Bhatia A. Treatment of neuropathic pain with venlafaxine: a systematic review. Pain Med 2017; 18: 1999-2012.","journal-title":"Pain Med"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Gallagher HC, Gallagher RM, Butler M, Buggy DJ and Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 2015: CD011091.","DOI":"10.1002\/14651858.CD011091"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00520-015-3009-x","article-title":"Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study","volume":"24","author":"Kus","year":"2016","unstructured":"Kus T, Aktas G, Alpak G, Kalender ME, Sevinc A, Kul S, Temizer M and Camci C. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study. Support Care Cancer 2016; 24: 2085-2091.","journal-title":"Support Care Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nrn1914","article-title":"Cancer pain and its impact on diagnosis, survival and quality of life","volume":"7","author":"Mantyh","year":"2006","unstructured":"Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 2006; 7: 797-809.","journal-title":"Nat Rev Neurosci"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Thong ISK, Jensen MP, Miró J and Tan G. The validity of pain intensity measures: what do the NRS, VAS, VRS, and FPS-R measure? Scand J Pain 2018; 18: 99-107.","DOI":"10.1515\/sjpain-2018-0012"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/pmt-2020-0036","article-title":"The visual time analog scale: simple, novel measurement approach to assess pain in patients with chronic pain","volume":"11","author":"Okifuji","year":"2021","unstructured":"Okifuji A, Mitsunaga R, Kida Y and Donaldson GW. The visual time analog scale: simple, novel measurement approach to assess pain in patients with chronic pain. Pain Manag 2021; 11: 357-368.","journal-title":"Pain Manag"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"104771","DOI":"10.1016\/j.jdent.2023.104771","article-title":"The Chinese version of the brief pain inventory-Facial (BPI-F) among different populations: factor structure and measurement invariance","volume":"139","author":"JJ","year":"2023","unstructured":"Lu JJ, Zhang FY, Feng Y, Yang YF, Guo Y and Feng YZ. The Chinese version of the brief pain inventory-Facial (BPI-F) among different populations: factor structure and measurement invariance. J Dent 2023; 139: 104771.","journal-title":"J Dent"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jad.2010.01.067","article-title":"Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis","volume":"126","author":"AJ","year":"2010","unstructured":"Mitchell AJ, Meader N and Symonds P. Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis. J Affect Disord 2010; 126: 335-348.","journal-title":"J Affect Disord"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Mossman SA, Luft MJ, Schroeder HK, Varney ST, Fleck DE, Barzman DH, Gilman R, DelBello MP and Strawn JR. The Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder: signal detection and validation. Ann Clin Psychiatry 2017; 29: 227-234A.","DOI":"10.1177\/104012371702900404"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2788.2005.00739.x","article-title":"Quality of life and its measurement: important principles and guidelines","volume":"49","author":"Verdugo","year":"2005","unstructured":"Verdugo MA, Schalock RL, Keith KD and Stancliffe RJ. Quality of life and its measurement: important principles and guidelines. J Intellect Disabil Res 2005; 49: 707-717.","journal-title":"J Intellect Disabil Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1081\/CNV-200032911","article-title":"Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress","volume":"22","author":"Hwang","year":"2004","unstructured":"Hwang SS, Scott CB, Chang VT, Cogswell J, Srinivas S and Kasimis B. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress. Cancer Invest 2004; 22: 678-687.","journal-title":"Cancer Invest"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Chen R, Coppes OJM and Urman RD. Receptor and molecular targets for the development of novel opioid and non-opioid analgesic therapies. Pain Physician 2021; 24: 153-163.","DOI":"10.36076\/ppj.2021.24.153-163"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1254\/jphs.FP0040252","article-title":"Involvement of peripheral mechanism in the verapamil-induced potentiation of morphine analgesia in mice","volume":"95","author":"Shimizu","year":"2004","unstructured":"Shimizu N, Kishioka S, Maeda T, Fukazawa Y, Dake Y, Yamamoto C, Ozaki M and Yamamoto H. Involvement of peripheral mechanism in the verapamil-induced potentiation of morphine analgesia in mice. J Pharmacol Sci 2004; 95: 452-457.","journal-title":"J Pharmacol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00540-020-02767-x","article-title":"A practical guide to acute pain management in children","volume":"34","author":"Gai","year":"2020","unstructured":"Gai N, Naser B, Hanley J, Peliowski A, Hayes J and Aoyama K. A practical guide to acute pain management in children. J Anesth 2020; 34: 421-433.","journal-title":"J Anesth"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s10865-014-9614-1","article-title":"Meaning in life in chronic pain patients over time: associations with pain experience and psychological well-being","volume":"38","author":"Dezutter","year":"2015","unstructured":"Dezutter J, Luyckx K and Wachholtz A. Meaning in life in chronic pain patients over time: associations with pain experience and psychological well-being. J Behav Med 2015; 38: 384-396.","journal-title":"J Behav Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","unstructured":"Farshchian N, Alavi A, Heydarheydari S and Moradian N. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018; 82: 787-793.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.55729\/2000-9666.1289","article-title":"Comparative study of the effects of duloxetine and venlafaxine on acute symptomatic taxane-induced neuropathy in breast cancer patients: a randomized clinical trial","volume":"14","author":"Radkhah","year":"2024","unstructured":"Radkhah H, Esfandbod M, Khadembashiri MA, Eslami M, Etesam F, Shahi F, Shobeir P and Rafiemehr M. Comparative study of the effects of duloxetine and venlafaxine on acute symptomatic taxane-induced neuropathy in breast cancer patients: a randomized clinical trial. J Community Hosp Intern Med Perspect 2024; 14: 18-24.","journal-title":"J Community Hosp Intern Med Perspect"}],"container-title":["American Journal of Translational Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:23:01Z","timestamp":1792660981000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/12\/ajtr0167632.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/nbwe4011","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}